<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418431</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0016</org_study_id>
    <nct_id>NCT00418431</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Central serous chorioretinopathy (CSC) has been known since it was first described by Von
      Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized
      disorder leading to serous neurosensory elevation of the central macula. The acute form of
      the disease is associated with focal leakage at the level of the retinal pigment epithelium
      (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the
      majority of patients, who also regain excellent vision. Occasionally, the neurosensory
      detachment persists and leads to pigment epithelial and photoreceptor damage with visual
      impairment.

      The purpose of this clinical study is report the use of intravitreal bevacizumab is a new
      option in the treatment of the chronic or recurrent CSC.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Central Serous Chorioretinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Any visual acuity.

          -  Central serous chorioretinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mitzy E Torres Soriano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitzy E Torres Soriano, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1172</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1171</phone_ext>
    <email>hugoquiroz@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociacion para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico DF</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitzy E Torres Soriano, MD</last_name>
      <phone>5255510841400</phone>
      <phone_ext>1171</phone_ext>
      <email>mitzytorres@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maura Abraham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Orlando Ustariz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerardo Garcia Aguirre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Kon-Jara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Quiroz-Mercado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose L Guerrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>January 3, 2007</last_update_submitted>
  <last_update_submitted_qc>January 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

